← Leaderboards
Eugenie S Kleinerman
University Of Texas Hlth Sci Ctr Houston
$6,577,718
Attributed
$6,577,718
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $610.7K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$6,577,718 · 8
By mechanism
R01$6,266,941 · 5
R56$241,820 · 1
M01$68,957 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineGene TherapyNeoplasm MetastasisLaboratoriesSignal TransductionPlayCellsChemotherapyOsteosarcomaLungTumorMouse ModelInvestigationMigrationGrantSiteChemotherapy-Oncologic ProcedureMetastatic Neoplasm To The LungAerosolsNeoplastic CellLiposomesAngiogenesisCyclophosphamideBase
Grant awards (34)
Regulation of Osteosarcoma Metastasis by Notch and Hes 1 Pathway Signaling$327,850
R01 · FY2015 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$69,905
R01 · FY2015 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$339,322
R01 · FY2014 · CA · contact PI
Preclinical Evaluation of ERBB Family Members as Therapeutic Targets in Osteosarc$60,613
R01 · FY2014 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy$246,403
R01 · FY2012 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy$246,403
R01 · FY2011 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$263,918
R01 · FY2010 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy$254,023
R01 · FY2010 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$92,714
R01 · FY2010 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$263,918
R01 · FY2009 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy$114,400
R01 · FY2009 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$86,240
R01 · FY2009 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$263,918
R01 · FY2008 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy$254,023
R01 · FY2008 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$86,240
R01 · FY2008 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$263,918
R01 · FY2007 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: Implications for Therapy$241,820
R56 · FY2007 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$41,323
R01 · FY2007 · CA · contact PI
Liposome and Polycationic Gene Therapy for Osteosarcoma$271,800
R01 · FY2006 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: useintherapy$241,820
R01 · FY2006 · CA · contact PI
Vasculogenesis in Ewing's Sarcoma: useintherapy$247,640
R01 · FY2005 · CA
VACDXR WITH OR WITHOUT IMMTHER FOR NEWLY DIAGNOSED HIGH RISK EWING'S SARCOMA$31,349
M01 · FY2005 · RR
LIPOSOME AND POLYCATIONIC GENE THERAPY FOR OSTEOSARCOMA$339,750
R01 · FY2004 · CA
Vasculogenesis in Ewing's Sarcoma: Implications for Ther$247,640
R01 · FY2004 · CA
VACdxr with or without ImmTher for Ewing's sarcoma$26,480
M01 · FY2004 · RR
LIPOSOME AND POLYCATIONIC GENE THERAPY FOR OSTEOSARCOMA$339,750
R01 · FY2003 · CA
LIPOSOME AND POLYCATIONIC GENE THERAPY FOR OSTEOSARCOMA$339,750
R01 · FY2002 · CA
VACDXR W/ OR W/OUT IMMTHER FOR NEWLY DIAGNOSED HIGH RISK EWINGS SARCOMA$0
M01 · FY2002 · RR
LIPOSOME AND POLYCATIONIC GENE THERAPY FOR OSTEOSARCOMA$339,750
R01 · FY2001 · CA
CHEMO/IMMUNOTHERAPY FOR HIGH RISK EWINGS SARCOMA$143,532
R01 · FY2001 · CA
VACDXR W/ OR W/OUT IMMTHER FOR NEWLY DIAGNOSED HIGH RISK EWINGS SARCOMA$0
M01 · FY2001 · RR
LIPOSOME AND POLYCATIONIC GENE THERAPY FOR OSTEOSARCOMA$339,750
R01 · FY2000 · CA
CHEMO/IMMUNOTHERAPY FOR HIGH RISK EWINGS SARCOMA$140,628
R01 · FY2000 · CA
VACDXR W/ OR W/OUT IMMTHER FOR NEWLY DIAGNOSED HIGH RISK EWINGS SARCOMA$11,128
M01 · FY2000 · RR